---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-044662"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:10:14.690580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AVROBIO reports positive clinical data for Gaucher gene therapy; plans Phase 2/3 trial for GD3 in H2 2023

## Summary
- GD3 pediatric patient (age 11) shows normalized GCase enzyme and biomarker; remains off ERT/SRT 15 months post AVR-RD-02; no new neurological signs.
- Four GD1 patients: liver volume reduced up to 24%, spleen up to 23%; lyso-Gb1 decreased 21%-70% below ERT baseline.
- AVROBIO plans global, randomized Phase 2/3 trial for GD3 in H2 2023, ~40 patients, 1:1 gene therapy vs. ERT, following FDA/MHRA feedback.
- No drug-related AEs; all AEs related to conditioning or underlying disease, mostly mild/moderate.
- plato platform late-stage ready; no major CMC changes anticipated for late-stage trials.

## SEC filing metadata
- accession: 0001140361-22-044662
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/0001140361-22-044662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/ny20005640x4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-044662
- JSON: https://secwatch.observer/filing/0001140361-22-044662.json
- Plain text: https://secwatch.observer/filing/0001140361-22-044662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.